Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

February 22, 2026

Study Completion Date

February 22, 2026

Conditions

Breast Cancer

Interventions

DRUG

[18F]FluorThanatrace

\[18F\]FluorThanatrace is a radiotracer for PET/CT

Trial Locations (1)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

lead

Abramson Cancer Center at Penn Medicine

OTHER